Client Testimonials
Over the years we have worked with many impactful businesses and have built long-standing relationships with our clients. Read the testimonials below to find out what our clients are saying about us and how we have been able to help them.
Replimune Inc.
“Over the past 2 years Cellomatics has been a reliable partner of Replimune, providing experimental support on several projects, as part of our clinical trial activities. Cellomatics expertise in routine blood handling, for the isolation of PBMC and immune cell sub-populations isolation, was a fantastic asset when processing, recording and storing patient samples. Cellomatics record keeping, and communication throughout each project has met our high expectations and has ensured the integrity of patient samples and data has been maintained.
Cellomatics has worked proactively, directly resolving issues with shipments and samples with our collection sites. They have also provided important feedback throughout each project to our clinical trials manager. In one instance, this feedback facilitated the trial manager in ensure all collection sites were conforming to the standardised process during sample collection. This action helped mitigate the risk of sample viability loss which was integral for a successful trial. Cellomatics has displayed great flexibility throughout our collaborations, as well as providing transparent and expert advice. We value the working relation formed with the Cellomatics team and see them as a preferential partner when considering future work that requires the input of a CRO.”
Dr Praveen Bommareddy, Senior Director of Translational Research
MicroA A.S.
“MicroA A.S. first approached Cellomatics when looking for a CRO with expertise in cell models of inflammatory processes, and in particular respiratory disease. We were impressed by the range of assays and flexible approach offered by Cellomatics. All communication was very efficient during development of our project proposal, and we were informed at all times about planning and progress. When required, Cellomatics did not hesitate to optimise procedures and carry out additional testing, and their attention to detail / data analysis was very reassuring. We are very pleased with their work and we would not hesitate to use their services again in the future.’’
Enrique Tabares, CEO
Nodthera Ltd
“Cellomatics’ exploratory work has helped crystallise our efforts on specific fluid biomarkers of interest to progress into further translational model.”
Pete Thornton, Director of Translational Science
Capella Biosciences Ltd
“I have worked with Cellomatics on three different therapeutic antibody projects with great success. One project entailed a novel cellular transport assay which Cellomatics set up from scratch. The other two projects involved primary cell based assays which Cellomatics proved to be exceptionally competent in. The project management was also very good with regular updates and emails with our team. Time wise the projects with Cellomatics ran smoothly and to plan. The quality of work and reports met all my expectations and I found the pricing to be very competitive compared to other quotations. Overall I would not hesitate to recommend them.”
Steve Holmes PhD, Former CEO
European Biotech
“A highly professional and thorough performance, excellent reproducibility of assay data provided by a diligently working team, led to a quick project advancement to the next stage as it allowed for a clear ranking of functional efficacy of several small molecule drugs supporting the selection of an early development candidate, and thus had a major strategic impact on our project status. It has been a pleasure to work together with Cellomatics and we are looking forward to continuing this highly efficient collaboration.”
Vice President, Drug Discovery and Development
LoQus 23 Therapeutics
“We have been delighted with our interactions with Cellomatics. When I first reached out to them after a recommendation from a former colleague (who also has very high standards) with the outline requirements for cell biology assay support, I was impressed by their review of the literature which was reflected in pro-actively suggesting additional, complementary assay options. This was further bolstered by exemplary attention to detail when putting together a work package proposal which was then efficiently executed. Even better, the interactions around the lab-based activities and data generation have been nothing short of ideal. The skillset, responsiveness, knowledge based, effort, effectiveness, transparent and regular communication are all outstanding. I have no hesitation whatsoever in recommending Cellomatics as an in vitro bioassay provider. We are increasingly viewing Cellomatics as our key go-to CRO for cell-biology activities to support our programmes. Our confidence in Cellomatics’ capabilities triggered the decision to engage further with additional decision-making activities critical for drug discovery and development.”
Dr Caroline Benn, CSO
LoQus 23 Therapeutics
“LoQus23 Therapeutics has the privilege of collaborating with Cellomatics on several pivotal projects. Their expertise has been instrumental in advancing our overall plans and securing essential funding. From the outset, Cellomatics has demonstrated excellent communication, ensuring that all project phases are seamlessly coordinated and that we are consistently aligned with our goals.
One of the significant impacts of Cellomatics’ services was the successful validation of our Lo-Q platform, which played a crucial role in our data package for obtaining additional seed funding. The miniaturization and reproducibility of key phenotypes enhanced our confidence in the platform’s suitability. Additionally, their biological interrogation against our lead target validated both the target and the platform, enabling a critical go/no-go decision to proceed with the shRNA library screen.
The completion of the shRNA library screening for unbiased target identification, focusing on the key phenotype of interest, was a significant milestone for us. This achievement, forming part of our milestone package, allowed us to release the second tranche of funding. It exemplifies our confidence in Cellomatics’ ability to help us deliver such critical outputs.
Moreover, Cellomatics plays a crucial role in testing compound dose responses from our med chem program within the Lo-Q platform assay. Their routine compound testing and cell viability assays are particularly valuable, ensuring consistent and reliable results.
Cellomatics has proven to be an invaluable partner in our drug discovery journey. Their contributions have significantly impacted our progress, reinforcing our commitment to continue collaborating with them in the future.”
Paulina Marzec, Senior Principal Scientist
Astra Zeneca, UK
“Cellomatics have been providing CRO support for AstraZeneca pre-clinical safety over the past 3 years. Working with their team of skilled scientists has enabled our timelines to progress with pace and agility. They have provided key quality datasets for IND submissions under pressure of aggressive time lines without faulter. We look forward to continuing our work together.”
Safety Scientist
Enveda Biosciences
“I have been working with Cellomatics for over 4 years in multiple projects in the areas of inflammation and oncology. Some of the projects were customized to suit our needs. The scientific team at Cellomatics were very efficient and proactive in helping us setting up the experiments. The project management team at Cellomatics has been doing a fantastic job by providing timely updates and regular communication. It has been an absolute pleasure working with Cellomatics and we look forward to more productive and fruitful collaboration in future.”
Indranil Mukhopadhyay, Assistant Vice President
Exvastat Ltd
“We were very impressed with the work that Cellomatics performed for us. This was not a straightforward model to establish and derive results in a short time frame, despite some literature references to base the work upon. Cellomatics produced a high quality report based on data that supported the original hypothesis.”
David Cavalla, CEO
European Biotech
“Working with the Cellomatics team was easy from initial discussions right through to project completion. They completed the project on time and in line with all of our desired objectives were met. Communication was regular, with results presented throughout the project, timelines were as agreed and the team went above and beyond to perform additional experiments based on results generated. The data generated was of high quality and met every expectation, we would happily work with them again.”
UK Biotech
“We contacted Cellomatics to perform pre-clinical studies to validate levels of our target present in plasma from cancer patients. Cellomatics quickly understood our needs and specification for the study. The assay was tech transferred to Cellomatics without any issues. Cellomatics provided regular communication during the study and completed the work on time and on budget. The final report was also completed and issued quickly following conclusion of the study. We would recommend Cellomatics for similar pre-clinical studies.”
Senior Scientific Manager
European Biotech
“As a small biotech relying on extensive outsourcing, we highly value Cellomatics’ expertise and ability to engage scientifically in our projects. Collaboration with the Cellomatics team has helped us move forward important strategic goals in our biomarker development.”
CSO
